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Abstract
Nonsteroidal anti-inflammatory drugs (NSAIDs) are highly effective
in treating the pain and inflammation associated with osteoarthritis
and rheumatoid arthritis, but it is well recognized that these agents
are associated with substantial gastrointestinal toxicity. Treatment
guidelines suggest that patients with one or more risk factors for
NSAID associated ulcers should be prescribed preventive
treatment. However, well over 80% of such patients may not
receive an appropriate therapeutic intervention. Multiple strategies
are available to reduce the risk for NSAID associated gastro-
intestinal complications. First, risk may be reduced by using non-
NSAID analgesics. Second, use of the minimum effective dose of
the NSAID may reduce risk. Third, co-therapy with a proton pump
inhibitor or misoprostol may be desirable in at-risk patients. Use of
cyclo-oxygenase-2 inhibitors may also reduce the risk for
gastrointestinal events, although this benefit is eliminated in
patients who receive aspirin, and cyclo-oxygenase-2 inhibitors may
increase cardiovascular adverse events. The optimal management
of NSAID related gastrointestinal complications must be based on
the individual patient’s risk factors for gastrointestinal and
cardiovascular disease, as well as on the efficacy and tolerability of
both the NSAID and accompanying gastroprotective agent.
Introduction
Nonsteroidal anti-inflammatory drugs (NSAIDs) are among
the most prescribed classes of medications worldwide, with
over 111 million prescriptions written between September
1999 and August 2000 [1]. In addition, more than 30 billion
over-the-counter (OTC) NSAID tablets are purchased
annually. NSAID use is common in all age groups, with most
frequent use among the elderly, of whom nearly 70% take
NSAIDs at least weekly.
The NSAIDs are highly effective in treating the pain and
inflammation associated with osteoarthritis (OA) and
rheumatoid arthritis (RA), but it is well recognized that these
agents are associated with an increased risk for upper
gastrointestinal toxicity, ranging from dyspepsia to gastro-
duodenal ulcers and bleeding. Although only a small
proportion of patients who use these agents develops gastro-
intestinal complications, the widespread use of these agents
magnifies the frequency into a large absolute number of
clinical gastrointestinal events. Individually and together, NSAID
related adverse events have an important impact on medical
outcomes, patient quality of life, and health care costs.
Treatment guidelines suggest that patients with one or more
risk factors for NSAID associated upper gastrointestinal tract
ulcer complications should be prescribed preventive treat-
ment. Despite these recommendations, gastroprotective
strategies (e.g. acid suppressive drugs, misoprostol, or
selective cyclo-oxygenase [COX]-2 inhibitors) appear to be
under-utilized in patients who receive NSAIDs. A retro-
spective observational cohort study conducted in The Nether-
lands [2], using data from early 1996 to mid-2002, found that
only 7.9% of NSAID users during this time period received a
preventive therapy. Of these, 6.6% received gastroprotective
agents, and an additional 1.3% received COX-2 inhibitors. A
greater percentage of patients with one or two risk factors for
upper gastrointestinal injury received gastroprotective drugs,
but well over 80% of these patients were provided with no
preventive strategy (Fig. 1). A large treatment gap persists,
despite an increase in the overall prevalence of use of
gastroprotective strategies from 5.1% in 1996 to 15.9% in
2002 [2].
Risk factors for NSAID related gastrointestinal
complications
In view of the recent controversies surrounding the cardio-
vascular effects of COX-2 selective agents, the number of
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patients who receive traditional NSAIDs is likely to increase
substantially. Consequently, the number at risk for NSAID
related gastrointestinal complications is also expected to
increase. Accurate identification of those who are at high risk
for NSAID related gastrointestinal toxicity is therefore
essential. (These issues are taken up in greater detail
elsewhere in this supplement [3].)
A number of factors have been identified that increase the
risk for NSAID associated upper gastrointestinal complica-
tions, including ulcers [4]. Use of multiple NSAIDs (including
OTC NSAIDs and aspirin) and high dosages of medication
increase risk. Interestingly, the greatest relative risk for
gastrointestinal complications exists during the first month of
treatment. Other important risk factors include prior ulcer
complications, advanced age, and concomitant corticosteroid
or anticoagulant use. The severity of RA may appear to
increase risk independently for adverse gastrointestinal
events. In contrast, dyspepsia and other upper gastro-
intestinal symptoms do not predict the development of upper
gastrointestinal events [1].
The role of Helicobacter pylori infection in NSAID associated
gastrointestinal disease remains somewhat controversial.
However, a recent meta-analysis [5] indicated that both
H pylori infection and NSAID use are independent risk factors
for gastrointestinal complications. It is clear that eradication
of the infection, although indicated in all patients with a
history of ulcer disease, is insufficient to reduce the NSAID
associated risk for ulcer and its associated complications.
Pharmacotherapeutic strategies for
prevention and treatment of NSAID related
ulcers
Several strategies are available to reduce the risk for NSAID
associated gastrointestinal adverse events. First, risk may be
reduced by the use of non-NSAID analgesics such as
acetaminophen, but this strategy is unlikely to be sufficient in
all patients or in those with more severe disease. Second, the
use of the minimum effective dose of NSAID may reduce the
risk for complications. Third, co-therapy with gastroprotective
agents may be necessary in patients at high risk for complica-
tions. Although these agents reduce the risk for gastro-
intestinal events, each is associated with its own spectrum of
side effects. In addition, increased medication burden (cost
and compliance issues) must be considered, particularly in
elderly patients who are likely to be receiving multiple
medications for concomitant conditions. Recommendations
for the treatment of NSAID related dyspepsia and mucosal
injury are summarized in Table 1 [6].
Finally, the use of COX-2 inhibitors may reduce the risk for
gastrointestinal events. However, this benefit is eliminated in
patients who receive aspirin, and COX-2 inhibitors may also
be associated with increased risk for adverse cardiovascular
events.
Misoprostol
The efficacy of misoprostol, a synthetic prostaglandin E1
analog, as prophylaxis for NSAID related gastric ulcers has
been demonstrated in several trials. In one study [7] 638
patients who were taking a traditional NSAID but did not have
a gastric or duodenal ulcer at screening were randomly
assigned to 12 weeks of treatment with misoprostol 200 µg
or placebo four times daily. Endoscopy was performed at
baseline and after 4, 8, and 12 weeks. In the intent-to-treat
population, 1.9% of those receiving misoprostol and 7.7% of
those in the placebo arm developed a gastric ulcer.
In a second study [8] 8843 ulcer free patients receiving
continuous therapy with NSAIDs were randomly assigned to
therapy with misoprostol 200 µg/day or placebo four times
daily. The primary outcome measure was the development of
serious upper gastrointestinal complications, as detected by
clinical symptoms or findings. Over the course of the 6-month
study, the incidence of serious upper gastrointestinal
complications was 40% lower among patients who received
misoprostol than among those who received placebo. More
Figure 1
Underutilization of preventive strategies in patients receiving NSAIDs. (a) Patients with one risk factor for upper gastrointestinal ulcer
complications. (b) Patients with two or more risk factors for upper gastrointestinal ulcer complications. Percentages total more than 100% because
of rounding. COX, cyclo-oxygenase; GPA, gastroprotective agent; NSAID, nonsteroidal anti-inflammatory drug. Reproduced with permission from
Oxford University Press [2].S25
patients in the misoprostol group (42%) than in the placebo
group (36%) withdrew from therapy, primarily because of
gastrointestinal side effects (e.g. diarrhea, abdominal pain,
and flatulence).
Although these data indicate that misoprostol is effective in
the prevention of ulcers, poor compliance because of the
relatively high rate of adverse events and the need for
frequent dosing are important concerns. One study [9] found
that lower doses of misoprostol are better tolerated.
However, the drug had to be taken at least twice daily to
provide effective prophylaxis against NSAID related ulcers as
quantified by endoscopy. Outcomes data are not available for
such lower dosages.
Misoprostol may also be effective in the treatment of patients
with established NSAID associated ulcers, but comparative
studies suggest that proton pump inhibitors (PPIs) are
substantially more effective in these patients [10].
The potential for poor compliance with misoprostol may, in
part, be reduced by fixed dose combinations of misoprostol
with an NSAID. Arthrotec® (Pfizer, Inc., New York, USA), a
combination agent consisting of diclofenac 50 mg or 75 mg
plus misoprostol 200 µg, was evaluated in a clinical study
that enrolled 572 patients with symptomatic OA of the knee
or hip and a history of gastric or duodenal ulcers or 10 or
more erosions [11]. In this study, endoscopically diagnosed
ulcers were significantly less frequent in patients receiving
the combination agent than in those receiving diclofenac
alone. Outcomes data are not available for this combination.
Sucralfate
Sucralfate, a basic aluminum salt of sucrose octasulfate,
forms an ulcer adherent complex at duodenal ulcer sites,
protecting the ulcer and promoting healing. It may also inhibit
pepsin activity in gastric fluid. Sucralfate has been shown to
be effective in the treatment of NSAID associated duodenal
ulcers, particularly when the NSAID is stopped, but it is not
effective in the treatment or prevention of NSAID related
gastric ulcers [6]. Its use is not recommended because of the
availability of far superior therapeutic options.
H2 receptor antagonists
H2 receptor antagonists modulate gastric pH through the
competitive inhibition of the action of histamine at H2
receptor sites on the gastric parietal cell. The efficacy of the
H2 antagonist famotidine at high dose (double the usual
dose) for preventing ulcers in patients receiving long-term
therapy with NSAIDs was examined in a double blind, parallel
group, randomized study conducted in patients with RA or
OA [12]. A total of 285 patients were randomly assigned to
therapy with famotidine (20 mg or 40 mg twice daily) or
placebo, and followed for 24 weeks for the incidence of
gastric or duodenal ulceration. Gastric ulcers were observed
in 13% and 8% of patients receiving the 20 mg and 40 mg
dosages of famotidine, respectively, and in 20% of patients in
the placebo group (P = 0.03 for famotidine 40 mg versus
placebo). The percentages of patients with gastroduodenal
ulcers were significantly lower in the famotidine 20 mg group
(4%) and the 40 mg group (2%) compared with the placebo
group (13%).
Although this agent has been shown to be effective in
preventing ulcers in patients taking NSAIDs in this single
study, H2 receptor antagonists are not recommended for
routine treatment of asymptomatic patients for a variety of
reasons, including their potential to mask dyspeptic
symptoms associated with mucosal injury [6]. Furthermore,
data suggest that the H2 receptor antagonists are less
effective in healing gastroduodenal ulcers than are PPIs,
whether or not NSAIDs are continued, and are inferior in
preventing ulcer recurrence [13,14].
Proton pump inhibitors
Unlike the H2 receptor antagonists, PPIs act by binding
irreversibly to resident proton pumps (H+/K+-ATPase), thus
inhibiting the final common pathway for acid secretion. PPIs
are administered as prodrugs that are activated in the acidic
environment of the parietal cell secretory canaliculus [15].
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Table 1
Recommendations for the treatment of NSAID related dyspepsia and mucosal injury
Clinical situation Recommendation
Dyspepsia Empirical treatment with H2 receptor antagonist or PPI; individualize therapy
Helicobacter pylori infection Treatment to eradicate infection in patients with a history of peptic ulcer; PPI therapy 
Active gastroduodenal ulcer
NSAID discontinued Treatment with H2 receptor antagonist or a PPI
NSAID continued Treatment with a PPI
Prophylactic therapy Treatment with a PPI or misoprostol or a COX-2 (preferential) or selective NSAID
COX, cyclo-oxygenase; NSAID, nonsteroidal anti-inflammatory drug; PPI, proton pump inhibitor. Adapted, with permission, from [6]. Copyright ©
1999 Massachusetts Medical Society. All rights reserved.S26
Once converted to their active form, PPIs bind to cysteine
residues in the proton pump and inhibit acid secretion into
the canalicular lumen [16].
Ulcer healing and prevention of relapse
Several large scale clinical trials have compared the
efficacies of PPIs and H2 receptor antagonists in patients
with established ulcers. In one trial [13] 541 patients with an
ulcer or more than 10 erosions were randomly assigned to
receive omeprazole 20 mg/day or 40 mg/day, or ranitidine
150 mg twice daily. Healing of gastric lesions was observed
in significantly more patients who received omeprazole (80%)
than in those who received ranitidine (61%; P < 0.001). Ulcer
healing was substantially more rapid with the PPI than with
the H2 receptor antagonist.
In another trial [14] 353 patients with confirmed gastric
ulcers were randomly assigned to therapy with lansoprazole
15 mg/day or 30 mg/day, or ranitidine 150 mg twice daily.
After 8 weeks of therapy, ulcer healing rates in the lanso-
prazole group ranged from 69% to 73%, as compared with
53% for ranitidine.
The efficacies of PPIs and misoprostol have also been
compared in several studies conducted in patients with
established ulcers and erosions. In a double blind study
conducted by Hawkey and colleagues [10] 935 patients who
had developed ulcers or more than 10 erosions in the
stomach or duodenum, or both, were randomly assigned to
4–8 weeks of therapy with omeprazole (20 mg/day or
40 mg/day) or 200 µg misoprostol four times daily. Patients
in whom treatment was successful were re-randomized to
treatment with 20 mg/day omeprazole, 200 µg misoprostol
twice daily, or placebo for an additional 6-month maintenance
phase. Patients were assessed clinically and endoscopically
during both phases. Treatment success, defined as the
absence of ulcers or the presence of fewer than five erosions
at each site and no more than mild dyspepsia, was observed
in 76% and 75% of patients receiving omeprazole 20 mg/day
and 40 mg/day, respectively, and in 71% of those given
misoprostol. The rate of gastric ulcer healing was significantly
higher in patients receiving the 20 mg dosage of omeprazole
(87%) than in those receiving misoprostol (73%); the rate of
duodenal ulcer healing was higher in the omeprazole 20 mg
and 40 mg groups (93% and 89%, respectively) than in the
misoprostol group (77%). The percentage of patients with
moderate or severe dyspepsia declined to a significantly
greater extent in the omeprazole 40 mg group than in the
misoprostol group. During the maintenance phase, signifi-
cantly fewer patients in the omeprazole 20 mg/day group
than in the misoprostol group suffered a relapse (27% of
patients in the placebo group).
A prospective, double blind, active and placebo controlled
study conducted by Graham and colleagues [17] compared
the efficacy of lansoprazole and misoprostol in the prevention
of ulcer recurrence among patients with a history of
endoscopically detectable gastric ulcers who were free from
H pylori infection at baseline. A total of 537 patients were
randomized to 12 weeks of therapy with 30 mg/day
lansoprazole, 15 mg/day lansoprazole, misoprostol 200 µg
four times daily, or placebo. The primary end-point was ulcer
status as determined by endoscopy. Evaluable patients in the
lansoprazole groups remained free from gastric ulcer
significantly longer than those who received placebo but for a
shorter time than those who received misoprostol. After
12 weeks of therapy, 93% of patients in the misoprostol
group were free from gastric ulcers, compared with 80% and
82% in the lansoprazole 15 mg and 30 mg groups.
Significantly more patients in the misoprostol groups
reported treatment related adverse events and withdrew from
the study. When withdrawal from the study was considered
as a treatment failure, lansoprazole and misoprostol were
clinically equivalent.
Outcome studies with proton pump inhibitors
The efficacy of PPIs in the prevention of recurrences of ulcer
complications from long-term, low-dose aspirin use was
examined in a trial conducted in 123 patients in Hong Kong
[18]. All patients initially received antibiotic treatment for
H pylori plus 30 mg lansoprazole twice daily, followed by
treatment with famotidine 20 mg twice daily for 5 weeks.
Patients with healed ulcers and in whom H pylori infection
had been eradicated were randomized to 12 months of
therapy with aspirin 100 mg/day plus lansoprazole 30 mg/day
or to aspirin plus placebo. Recurrence of ulcer complications
was observed in 1.6% of patients in the lansoprazole group
(one episode of gastrointestinal bleed) and in 14.8% of those
in the placebo group (nine gastrointestinal bleeds). After
controlling for confounding covariates, patients who received
placebo were at a 9.6-fold increased risk for recurrent ulcers.
Similarly, a study conducted by Chan and colleagues [19]
demonstrated that PPIs are superior in preventing recurrent
ulcer complications in patients receiving aspirin or other
NSAIDs who were also infected with H pylori. In this study,
400 patients with a history of upper gastrointestinal bleeding
were treated with omeprazole 20 mg/day until ulcer healing,
and then assigned to treatment with omeprazole 20 mg/day
or to 1 week of H pylori eradication therapy. Patients
previously receiving aspirin were treated with aspirin
80 mg/day; those receiving NSAIDs took naproxen 500 mg
twice daily. The risk for recurrent bleeding was 1.9% in
aspirin patients who received eradication therapy and 0.9%
in those who received omeprazole; among patients receiving
other NSAIDs the corresponding risks were 18.8% with
eradication therapy and 4.4% with omeprazole.
COX-2 inhibitors
The reduction in incidence of gastrointestinal complications
in patients receiving COX-2 inhibitors is reviewed elsewhere
in this supplement [3]. Given recent concerns regarding the
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cardiovascular safety of this class of medications, and
additional data showing that the incidence of gastrointestinal
complications is not reduced in patients who receive
concomitant aspirin, the risks and benefits of COX-2
inhibitors must be carefully balanced when considering
therapy with these agents. In light of these concerns, in July
2005 the US Food and Drug Administration recommended
labeling changes for OTC and prescription NSAIDs,
including COX-2 selective NSAIDs, that include a boxed
warning highlighting the potential not only for increased risk
for cardiovascular events but also for life-threatening
gastrointestinal bleeding associated with their use [20].
Existing arthritis treatment guidelines, published before the
COX-2 cardiovascular safety controversy, recommend that
patients at risk for ulcer disease who require treatment for
arthritis receive either COX-2 selective agents or a
nonselective NSAID in combination with a PPI [21-23]. The
relative efficacies of these strategies were compared in a
randomized, controlled study conducted in 287 patients who
had used NSAIDs for arthritis and had a history of ulcer
bleeding [24]. Patients were randomized to 6 months of
therapy with celecoxib 200 mg twice daily plus daily placebo
or 75 mg diclofenac twice daily plus 20 mg/day omeprazole,
and followed for recurrent ulcer bleeding. The primary end-
point occurred in seven patients who received celecoxib and
nine patients who received diclofenac plus omeprazole; the
corresponding probabilities of recurrent bleeding during the
study were 4.9% and 6.4% (Fig. 2). Adverse events,
including hypertension, peripheral edema, and renal failure,
occurred in 24.3% and 30.8% of patients receiving celecoxib
and diclofenac plus omeprazole, respectively. Later analysis
of endoscopic data from this study [25] showed that neither
regimen prevented ulcer recurrence.
It should be noted, however, that additional long-term
outcomes studies will be necessary to quantify better the
benefits of PPI co-therapy for chronic NSAID users
compared with the selective COX-2 inhibitors with regard to
the risk for bleeding throughout the gastrointestinal tract,
because PPI co-therapy affects only injury in the acid
vulnerable proximal gastrointestinal tract.
Guidelines for anti-inflammatory therapy and
ulcer prophylaxis in the post-rofecoxib/
valdecoxib age
The decision by Merck to voluntarily withdraw rofecoxib from
the market (followed recently by the removal of valdecoxib
[Bextra®] by Pfizer) has had a profound impact on clinician
and patient choices regarding NSAIDs, COX-2 inhibitors, and
prophylactic therapy to prevent ulcers. Recently, a guide to
NSAID therapy in the post-rofecoxib/valdecoxib age was
proposed in the American Journal of Managed Care
(Table 2) [26]. It should be noted that these guidelines have
not been endorsed by a major medical society, but in light of
recent evidence they represent a reasonable approach to
selecting therapy for patients who require NSAIDs.
For patients without cardiovascular risk factors who require
aspirin prophylaxis and who are at low risk for gastrointestinal
Available online http://arthritis-research.com/content/7/S4/S23
Figure 2
Cumulative probability of recurrent ulcer bleeding in patients receiving celecoxib or diclofenac plus omeprazole. Reproduced with permission from
[24]. Copyright © 2002 Massachusetts Medical Society. All rights reserved.S28
events, monotherapy with a traditional NSAID remains the
initial approach to anti-inflammatory therapy. Data suggest
that strategies consisting of COX-2 inhibitors or NSAIDs plus
a PPI are equally effective in reducing the risk for ulcer
bleeding. Therefore, patients who do not require aspirin and
who are at relatively high risk for NSAID related gastro-
intestinal events may be prescribed a COX-2 inhibitor or an
NSAID with PPI co-therapy. In treating those with cardio-
vascular risk that requires aspirin prophylaxis, COX-2
inhibitors should generally be avoided; these patients should
receive a traditional NSAID plus a PPI if the absolute risk of a
gastrointestinal event warrants gastroprotection.
Conclusion
The management of NSAID related ulcer disease must be
individualized according to the patient’s risk factors for
gastrointestinal complications and cardiovascular disease, as
well as the efficacy and tolerability of both the NSAID and
gastroprotective co-therapy.
As discussed elsewhere in this supplement [3], the
concomitant use of aspirin, particularly in an older population
at generally higher cardiovascular risk, is an important factor
to consider. Although it is clear that COX-2 inhibitors reduce
the risk for gastrointestinal events, use of concomitant
aspirin negates the gastrointestinal benefits of COX-2
inhibitors. Moreover, use of certain NSAIDs such as
ibuprofen may interfere with the antiplatelet effect of aspirin.
In general, a strategy that carefully balances treatment
benefits, potential for gastrointestinal complications, and
cardiovascular risk is warranted in all patients who receive
NSAIDs.
Finally, given the widespread use of OTC NSAIDs, careful
attention should be paid to educating patients about the
gastrointestinal and cardiovascular risks associated with
NSAIDs and the potential for undesirable interactions among
these medications.
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